40807-61-2

Basic information

• Product Name: 4-HYDROXY-4-PHENYLPIPERIDINE
• Synonyms: 4-HYDROXY-4-PHENYLPIPERIDINE;LABOTEST-BB LT00233127;4-Hydroxy-4-phenylpiperadine;4-HYDROXY-4-PHENYLPIPERIDINE 99%;NSC 71658;4-PHENYL-PIPERIDIN-4-OL;4-PHENYL-4-PIPERIDINOL;4-PHENYL-4-HYDROXYPIPERIDINE
• CAS NO: 40807-61-2
• Molecular Formula: C₁₁H₁₅NO
• Molecular Weight: 177.24
• EINECS: 255-089-0
• Product Categories: PHARMACEUTICAL INTERMEDIATES;Piperidines, Piperidones, Piperazines;API intermediates;Building Blocks;Heterocyclic Building Blocks;Piperidines
• Mol File: 40807-61-2.mol
• Article Data: 12

Chemical Properties

• Melting Point: 157-161 °C(lit.)
• Boiling Point: 317.9 °C at 760 mmHg
• Flash Point: 137.2 °C
• Appearance: Pale brown/Solid
• Density: 1.093
• Vapor Pressure: 0.000157mmHg at 25°C
• Refractive Index: 1.559
• Storage Temp.: 2-8°C(protect from light)
• BRN: 141577
• CAS DataBase Reference: 4-HYDROXY-4-PHENYLPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXY-4-PHENYLPIPERIDINE(40807-61-2)
• EPA Substance Registry System: 4-HYDROXY-4-PHENYLPIPERIDINE(40807-61-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 40807-61-2(Hazardous Substances Data)

Usage

Uses

Reactant for synthesis of:Diaminotriazine hNav1.7 inhibitorsSelective σ?ligandsGlycogen synthase kinase-3β?inhibitorsDiphenylbutylpiperidines as cell autophagy inducersMalonyl-coA decarboxylase inhibitors with antiobesity and antidiabetic activitiesSelective dopamine D2 receptor antagonists

InChI:InChI=1/C11H15NO/c13-11(6-8-12-9-7-11)10-4-2-1-3-5-10/h1-5,12-13H,6-9H2

Upstream product

• 220525-47-3 4-Brom-4-phenyl-piperidin 
• 63843-83-4 1-benzyl-4-hydroxy-4-phenylpiperidine 
• 7647-01-0 hydrogenchloride 
• 19798-94-8 6-methyl-6-phenyl-[1,3]oxazinane 
• 172734-33-7 4-hydroxy-4-phenylpiperidine-1-carboxylic acid tert-butyl ester 
• 771-99-3 4-phenylpiperidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 100-58-3 phenylmagnesium bromide 
• 383865-57-4 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine 
• 98-88-4 benzoyl chloride 
• 108-86-1 bromobenzene 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 
• 1445-73-4 1-Methyl-4-piperidone 
• 41979-39-9 4-piperidone hydrochloride 

Downstream Products

• 103266-34-8 1-(2-benzhydryloxy-3-phenoxy-propyl)-4-phenyl-1,2,3,6-tetrahydro-pyridine 
• 63843-83-4 1-benzyl-4-hydroxy-4-phenylpiperidine 
• 102950-92-5 1-benzhydryl-4-phenyl-1,2,3,6-tetrahydro-pyridine 
• 3109-12-4 4-(4-hydroxy-4-phenyl-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone 
• 14862-80-7 4-(4-hydroxy-4-phenylpiperidin-1-yl)-1-phenylbutan-1-one 
• 14769-58-5 5-[2-(4-hydroxy-4-phenyl-piperidin-1-yl)-ethyl]-oxazolidin-2-one 
• 14769-57-4 3-benzyl-5-[2-(4-hydroxy-4-phenyl-piperidin-1-yl)-ethyl]-oxazolidin-2-one 
• 49798-07-4 5-[2-(4-hydroxy-4-phenyl-piperidin-1-yl)-ethyl]-3-methyl-oxazolidin-2-one 
• 104853-17-0 3-(4-Hydroxy-4-phenyl-piperidin-1-ylmethyl)-3H-benzooxazol-2-one 
• 87602-53-7 1-(2,6-Dimethyl-quinolin-4-yl)-4-phenyl-piperidin-4-ol 
• 87602-62-8 1-(6-Methoxy-2-methyl-quinolin-4-yl)-4-phenyl-piperidin-4-ol 
• 169332-15-4 1-<4-<(triisopropylsilyl)oxy>phenyl>-2-(4-hydroxy-4-phenylpiperidino)-1-propanone 
• 5193-57-7 3-(4-hydroxy-4-phenylpiperidin-1-yl)propanenitrile 
• 193882-53-0 2-[3-(4-Hydroxy-4-phenyl-piperidin-1-yl)-propyl]-isoindole-1,3-dione 

Relevant articles and documents

Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor

Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure-kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles.

Synthesis and biological evaluation of picolinamides as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)

Synthesis of a series of 6-substituted picolinamide derivatives and their inhibitory activities against 11β-hydroxysteroid dehydrogenase type 1 are described. Optimization of the initial hit compound, N-cyclohexyl-6-(piperidin-1-yl)picolinamide (1) from high throughput screening of in-house library resulted in the discovery of the highly potent and metabolically stable compound 25, which was efficacious in a mouse ex vivo pharmacodynamic model and reduced the fasting blood glucose and insulin levels in a HF/STZ mouse model after oral dosing.

Synthesis and SAR study of diphenylbutylpiperidines as cell autophagy inducers

A novel series of diphenylbutylpiperidines as autophagy inducers was described and extensive SAR studies resulted in derivatives (15d-e, 15i-j) with 10-fold greater activity than the lead compounds 1 and 2. Meanwhile, a new synthetic route to diphenylbutyl bromide (6) from bromobenzene and γ-butyrolactone was also reported here.